Yılmaz Mesut, Kilic Selcuk, Bayrakdar Fatma, Ötgün Selin Nar, Tosun Ayse Istanbullu, Zeybek Umit, Çelik Faruk, Aygun Gokhan, Safak Birol, Mahroum Naim
Infectious Diseases and Clinical Microbiology, International School of Medicine, Istanbul Medipol University, Istanbul 34810, Turkey.
Public Health General Directorate, Department of Microbiology Reference Laboratories and Biological Products, Ankara 06430, Turkey.
Diagnostics (Basel). 2025 May 13;15(10):1228. doi: 10.3390/diagnostics15101228.
If used in the right clinical context, PCRs carry great potential in rapidly diagnosing various infectious diseases. We aimed to evaluate the clinical performance of four novel multiplex real-time PCR (qPCR) assays in the direct detection of pathogens in whole blood, cerebrospinal fluid, respiratory specimens, and stool samples. Spiked negative clinical specimens were used for the evaluation. Clinical samples for the comparative assessment of culture and molecular analyses were simultaneously examined. RINA robotic nucleic acid isolation system and Bio-Speedy multiplex qPCR panels (Bioeksen R&D Technologies, Turkey), and the LightCycler 96 Instrument (Roche, USA) were used for the molecular testing. No qPCR assays produced positive results for the samples spiked with the potential cross-reacting pathogens. The limit of detection (LOD) of the assays changed with the use of 10 and 100 pathogens/mL sample based on the target and sample type. The relative sensitivity and specificity of the assays were, respectively, 82% and 94% for blood, 97.1% and 99.3% for blood culture, 94% and 98% for stool, 96% and 97% for CSF, and 97% and 96% for respiratory specimens. The panels evaluated allow the direct molecular analysis of 10 samples from four clinical syndromes on the same run in 3 h with high clinical performance. The number and variety of samples in a single run enable healthcare providers to rapidly and efficiently diagnose and treat various infections.
如果在合适的临床环境中使用,聚合酶链反应(PCR)在快速诊断各种传染病方面具有巨大潜力。我们旨在评估四种新型多重实时PCR(qPCR)检测方法在直接检测全血、脑脊液、呼吸道标本和粪便样本中的病原体时的临床性能。使用加标的阴性临床标本进行评估。同时检查用于培养和分子分析比较评估的临床样本。分子检测使用RINA机器人核酸提取系统和Bio-Speedy多重qPCR检测板(土耳其Bioeksen研发技术公司)以及LightCycler 96仪器(美国罗氏公司)。对于加标有潜在交叉反应病原体的样本,没有qPCR检测方法产生阳性结果。根据目标和样本类型,检测方法的检测限随每毫升样本中使用10个和100个病原体而变化。检测方法的相对灵敏度和特异性在血液中分别为82%和94%,在血培养中为97.1%和99.3%,在粪便中为94%和98%,在脑脊液中为96%和97%,在呼吸道标本中为97%和96%。所评估的检测板能够在3小时内对来自四种临床综合征的10个样本进行同批直接分子分析,且具有较高的临床性能。单次运行中样本的数量和种类使医疗服务提供者能够快速、高效地诊断和治疗各种感染。